Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX: WEED) (NYSE: CGC) is pleased to introduce Spectrum Therapeutics, a new global brand that will encompass all of the Company's ongoing medical and research operations including Spectrum Cannabis, Canopy Health Innovations (CHI), and the most recent addition to Canopy Growth's medical portfolio, Bionorica SE-founded C(3) Cannabinoid Compound Company ("C(3)"), a European leader in cannabinoid-based medical therapies.
Incorporating these entities into one unified ecosystem will integrate the Company's medical efforts as one global healthcare enterprise. Spectrum Therapeutics now encompasses the production and distribution of full-spectrum medical cannabis products, industry-leading education, resources and support for patients and healthcare practitioners along with clinical research and the development of cannabinoid-based medicines.
The recent acquisition of C(3) will allow Spectrum Therapeutics to continue to advance leadership in medical cannabis globally by further expanding its ability to empower physicians in Europe and around the world with the knowledge and therapies drawn from a full range of cannabinoid-based medicines. This includes dronabinol, C(3)'s cannabinoid pharmaceutical drug available in Germany, Austria, Switzerland, and Denmark. Dronabinol, while integrated into the Spectrum Therapeutics' commercial offering, will continue to be marketed under C(3)'s brand, Bionorica Ethics.
"We've always been a company that provides more than medical cannabis to our patients,"
